Updated Monday, 2/23. The typical February lull has taken hold of the IPO market while issuers work on year-end audited financials, but one sizable biotech is scheduled to go public before month end. Small deals may also join the calendar throughout the week. ...read more
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1...read more
November’s IPO market struggled to take off amid a US government shutdown at the start of the month and a slump in tech stocks. Even still, eleven new listings managed to raise a combined $2.3 billion, below the month’s historical 10-year average...read more
US IPO Week Ahead: Asthma biotech set to close out February IPO market
Updated Monday, 2/23. The typical February lull has taken hold of the IPO market while issuers work on year-end audited financials, but one sizable biotech is scheduled to go public before month end. Small deals may also join the calendar throughout the week. ...read more
US IPO Week Ahead: Markets set for a quiet week after year’s first sizable IPO
...read more
US IPO Week Ahead: Aktis Oncology set to open 2026 IPO Market
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1 ...read more
Renaissance Capital's November IPO Market Update
November’s IPO market struggled to take off amid a US government shutdown at the start of the month and a slump in tech stocks. Even still, eleven new listings managed to raise a combined $2.3 billion, below the month’s historical 10-year average...read more